AstraZeneca Explores Cancer Vaccine Development, CEO Soriot Says

AstraZeneca Plc is considering developing cancer vaccines, a potential strategic expansion into one of the most active fields of oncology research, according to comments from its chief executive. The move would see the UK drugmaker enter a competitive space where rivals are already advancing new therapeutic technologies.

CEO Signals New R&D Direction

Speaking to analysts at the recent European Society For Medical Oncology conference in Madrid, CEO Pascal Soriot confirmed that cancer vaccines have been the subject of significant internal discussion. He highlighted the company's work in messenger RNA (mRNA) technology, which was central to its COVID-19 vaccine developed with Oxford University.

"Our R&D team has done a lot of work in the last couple of years on mRNA technology," Soriot said. "We believe we can actually do something in the field, and you'll hear more about this in the months and years to come."

Defining a Strategy

The company appears to be carefully weighing its approach. Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, noted that other companies may be better positioned to advance personalized cancer vaccines, which are tailored to an individual patient's tumor.

Ad

Fredrickson suggested AstraZeneca's focus could instead be on non-personalized vaccines, which are designed to treat a broader population of patients with a similar type of cancer. He stated that the company's infectious diseases group is interested in this area.

Competitive Landscape

AstraZeneca's potential entry comes as the cancer vaccine field gains momentum. The technology has shown significant promise in early trials, attracting major investment from pharmaceutical companies.

A prominent example is a personalized melanoma vaccine being co-developed by Moderna and Merck & Co. Early results showed it reduced the likelihood of patients' tumors returning by 42%, underscoring the high bar for new entrants and the potential rewards in the market.